Loading
CAR-T Cell Therapy Research / Virus-based Gene Therapy Research / CRISPR and Genetic Engineering · Journal article
International Journal on Science and Technology · August 12, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review examining CRISPR-based engineering of immune cells (CAR-T, NK cells, macrophages) for cancer immunotherapy. It discusses mechanistic foundations, technological innovations, and preclinical/clinical advancements without reporting original trial results or comparative effectiveness data. The evidence base remains exploratory, addressing how CRISPR might overcome CAR-T limitations rather than demonstrating that it does so in practice.
Narrative review. Patients with hematologic and solid cancers; immuno-oncology field broadly..
CRISPR enables precise gene knockout, targeted gene insertion, epigenetic modulation, and multiplex editing of immune cells. CAR-T therapy has demonstrated efficacy in hematologic cancers but faces persistent challenges including limited durability, immune escape, toxicity, and poor solid tumor performance. CRISPR-based approaches have advanced CAR-T cell engineering and catalyzed development of next-generation immune effectors including natural killer cells, macrophages, and stem cell-derived immune populations.
No specific effect sizes, response rates, survival data, or safety metrics provided. CAR-T therapy has demonstrated efficacy in hematologic cancers but faces persistent challenges including limited durability, immune escape, toxicity, and poor solid tumor performance.
This review frames CRISPR-based immune engineering as a conceptual and technological advance with potential to address known CAR-T limitations, but does not provide clinical trial evidence or efficacy benchmarks to guide current clinical decision-making. Clinicians should recognize this as a landscape synthesis of emerging tools, not an evidence base for practice change.
This is a narrative review synthesizing mechanistic concepts and preclinical advances in CRISPR-based immune engineering, without reporting original empirical results, clinical outcomes, or comparative efficacy data.
As stated by the source record.
This review frames CRISPR-based immune engineering as a conceptual and technological advance with potential to address known CAR-T limitations, but does not provide clinical trial evidence or efficacy benchmarks to guide current clinical decision-making. Clinicians should recognize this as a landscape synthesis of emerging tools, not an evidence base for practice change.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Immuno-oncology has reshaped the therapeutic landscape of cancer treatment by shifting focus from directly targeting tumor cells to mobilizing the immune system against malignancies. Among the most transformative advances in this field is the development of chimeric antigen receptor T-cell therapy, which has demonstrated remarkable efficacy in hematologic cancers. However, persistent challenges such as limited durability, immune escape, toxicity, and poor performance in solid tumors have constrained its broader clinical impact. The emergence of clustered regularly interspaced short palindromic repeats (CRISPR) genome editing has introduced a powerful and versatile platform for engineering immune cells with enhanced specificity, persistence, and functionality. CRISPR-based approaches enable precise gene knockout, targeted gene insertion, epigenetic modulation, and multiplex editing, allowing researchers to redesign immune cells at multiple regulatory levels. These capabilities have significantly advanced CAR-T cell engineering and have catalyzed the development of next-generation immune effectors, including natural killer cells, macrophages, and stem cell-derived immune populations. Furthermore, CRISPR technology has opened new avenues for overcoming the immunosuppressive tumor microenvironment, improving safety profiles, and enabling scalable, off-the-shelf therapies. This review provides a comprehensive examination of CRISPR applications in immuno-oncology, with an emphasis on CAR-T optimization and the engineering of next-generation immune cells. It discusses mechanistic foundations, technological innovations, preclinical and clinical advancements, safety considerations, and future directions. Collectively, CRISPR-driven immune engineering represents a paradigm shift toward more precise, effective, and accessible cancer immunotherapies.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.